Half the dosage, similar efficacy, less bleeding: The new tissue plasminogen activator regimen for pulmonary embolism?

Chest

Volumn 137, Issue 2, 2010, Pages 245-247

  Davidson, Bruce L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLACEBO; THROMBOPLASTIN; UROKINASE; WARFARIN;

DRUG EFFICACY; EDITORIAL; HUMAN; LUNG EMBOLISM; LUNG HEMODYNAMICS; LUNG HEMORRHAGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 76749146421     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-2156     Document Type: Editorial

References (15)

1. Wang C, Zhai Z, Yang Y, et al; for the China Venous Thromboembolism (VTE) Study Group. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism:a randomized, multicenter, controlled trial. Chest. 2010;137(2):254-262.
2. Ross AM, Gao R, Coyne KS, et al; TUCC Investigators. A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial. Am Heart J. 2001;142(2):244-247.
3. Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet. 1988;2(8606):293-298.
4. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines(8th edition). Chest. 2008;133(6 suppl):454S-545S.
5. Goldhaber SZ, Agnelli G, Levine MN; The Bolus Alteplase Pulmonary Embolism Group. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. Chest. 1994;106(3):718-724.
6. Lubenow N, Eichler P, Lietz T, Greinacher A; HIT Investigators Group. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005;3(11):2428-2436.
7. Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost. 2009;7(suppl 1):9-12.
8. Niewoehner DE, Erbland M, Collins D. Glucocorticoids for chronic obstructive pulmonary disease. N Engl J Med. 1999;341(23):1772-1773.
9. Ibrahim SA, Stone RA, Obrosky DS, Geng M, Fine MJ, Aujesky D. Thrombolytic therapy and mortality in patients with acute pulmonary embolism. Arch Intern Med. 2008;168(20):2183-2190.
10. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation. 2004;110(6):744-749.
11. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry(ICOPER). Lancet. 1999;353(9162):1386-1389.
12. Dalen JE, Alpert JS, Hirsh J. Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? When is it indicated? Arch Intern Med. 1997;157(22):2550-2556.
13. Carlbom DJ, Davidson BL. Pulmonary embolism in the critically ill. Chest. 2007;132(1):313-324.
14. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W; Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347(15):1143-1150.
15. Meneveau N, Séronde MF, Blonde MC, et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest. 2006;129(4):1043-1050.